不仅仅是另一种IDH抑制剂:来自HMPL-306第一阶段试验的见解
Ted M Getz1, Jan Philipp Bewersdorf1
1Section of Hematology, Department of Internal Medicine, Yale University and Yale Comprehensive Cancer Center, New Haven, CT 06520, USA.
Med (New York, N.Y.)
|June 14, 2025
概括
新型双IDH1/2抑制剂HMPL-306在患有IDH突变的急性髓性白血病 (AML) 患者中显示出前景. 这一第一阶段的研究表明,这种具有挑战性的癌症具有可管理的安全性和有效的初步结果.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 对异酸脱酶 (IDH) 抑制剂的耐药性是急性髓性白血病 (AML) 的重大挑战.
- 对于针对AML的IDH突变的新型治疗策略有着至关重要的需求.
- IDH突变是AML病例的一个子集的关键驱动因素.
研究的目的:
- 评估HMPL-306的安全性和初步疗效,HMPL-306是一种新的IDH1和IDH2的双重抑制剂.
- 评估HMPL-306在复发/耐药IDH突变AML的患者中的治疗潜力.
主要方法:
- 第1阶段临床研究设计.
- 招募患有复发/耐药IDH突变AML的患者.
- 管理和监测HMPL-306.6.的管理和监测.
主要成果:
- 在研究人群中,HMPL-306显示出可管理的安全性.
- 观察到初步的疗效信号,表明治疗效益.
- 双IDH1/2抑制显示出治疗耐药AML的潜力.
结论:
- HMPL-306代表了一种对IDH突变AML的有前途的新型治疗剂.
- 该药物的安全性和有效性需要在更大的临床试验中进一步调查.
- HMPL-306可能为复发性/耐药性AML的患者提供一种有价值的新治疗选择.
相关概念视频
Clinical Trials
11.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
11.2K
Clinical Trials: Overview
5.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.5K
Preclinical Development: Overview
6.6K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.6K
Drug Administration and Therapy Phases: Overview
2.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
2.1K
Bioavailability Study Design: Single Versus Multiple Dose Studies
355
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
355
Bioavailability Study Design: Healthy Subjects Versus Patients
229
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
229


